Zhejiang Medicine shareholders approve 2025 restricted stock incentive plan

Zhejiang Medicine Co., Ltd. announced the successful approval of its 2025 Restricted Stock Incentive Plan at the first extraordinary general meeting of shareholders held on November 13, 2025. The plan received significant support, with 89.27% of A-share votes in favor for the plan's framework, assessment methods, and authorizing the board to manage related matters. This plan, involving 102.84m restricted shares, represents 1.0694% of the company's total share capital and will be granted at a price of 7.30 yuan per share.

The incentive program spans two performance assessment years, 2026 and 2027, with two release periods. Performance will be evaluated across six business segments, including chemical and biological pharmaceutical R&D, nutritional products, pharmaceutical manufacturing, and commercial distribution. Eligibility for incentives is linked to achieving specific R&D milestones, gross profit growth targets, and net profit growth for various departments.

An internal self-inspection conducted prior to the announcement confirmed no insider trading activity among key personnel within six months before the plan's disclosure. This underscores the company's adherence to regulatory requirements and commitment to fair and transparent governance.